Veritas’ Research Arm Cannevert Signs Clinical Research Agreement for Human Studies to Assess its Lead Cannabis …

VANCOUVER, British Columbia, Jan. 10, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that its research arm, Cannevert Therapeutics Ltd. (“CTL”) has signed a clinical research agreement with the FDI Clinical Research (FDI-CR) in San Juan, Puerto Rico, to conduct the first human study of its lead cannabis strain (CTL-X) targeting pain.

This announcement follows a previous release (November 20, 2017), in which CTL announced the signing of a Letter of Intent with FDI-CR to conduct a human study of CTL-X in two stages. The first stage will have an open label design to look at the feasibility of two doses of CTL-X in 5 subjects while the second stage will use a randomized, double-blind, crossover design to assess one dose of CTL-X against a placebo control strain in 16 subjects

... read more at: